Tolgabide

Tolgabide
Clinical data
ATC code
  • none
Legal status
Legal status
  • Investigational
Identifiers
IUPAC name
  • 4-{[(E)-(3-Chloro-5-methyl-6-oxocyclohexa-2,4-dien-1-ylidene)(4-chlorophenyl)methyl]amino}butanamide
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC18H18Cl2N2O2
Molar mass365.25 g·mol−1
3D model (JSmol)
SMILES
  • Cc1cc(cc(c1O)/C(=N/CCCC(=O)N)/c2ccc(cc2)Cl)Cl
InChI
  • InChI=1S/C18H18Cl2N2O2/c1-11-9-14(20)10-15(18(11)24)17(22-8-2-3-16(21)23)12-4-6-13(19)7-5-12/h4-7,9-10,24H,2-3,8H2,1H3,(H2,21,23)/b22-17+
  • Key:AOAFGVWKONLQRN-OQKWZONESA-N

Tolgabide (INN; development code SL-81.0142) is a drug which was patented by Synthélabo as an anticonvulsant but was never marketed.[1] It is an analogue of progabide and acts similarly to it as a prodrug of GABA, and therefore as an indirect agonist of the GABA receptors.[1][2]

See also

References

  1. 1 2 Triggle DJ (1996). Dictionary of Pharmacological Agents. Boca Raton: Chapman & Hall/CRC. ISBN 0-412-46630-9.
  2. ↑ "The use of common stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances" (PDF). 2002.
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.